Leerink Partners still thinks Veradermics is a good buy and has increased its price target to $185.

Nov 13, 2026, 2:18 PM ETOpinionRead the original at moomoo.com

Good for MANE

Leerink kept its Buy rating and raised its target from $150 to $185, signaling a more favorable view. This is an analyst opinion, not a new company result.

MANE · Veradermics, Incorporated

AI read · Good for MANE

The AI's read

The firmer analyst view is favorable for how investors may see Veradermics. The story reports no new treatment, sales, or trial result, so the support comes from that opinion rather than a reported business change.

Get alerts for MANE

Follow Veradermics, Incorporated (MANE) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for MANE

Free on the App Store and Google Play, or on the web.